Innovation Pharmaceuticals

OverviewSuggest Edit

Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including Kevetrin, an anti-cancer compound that has completed Phase I clinical trial; and Prurisol, an anti-psoriasis drug candidate that is in Phase II clinical trial. It also focuses on the development of Brilacidin, an antibiotic candidate for the treatment of acute bacterial skin and skin structure infection, oral mucositis, and inflammatory bowel disease, and ulcerative proctitis/colitis; and defensin-mimetics for otic infections, diabetic foot infections, and hidradenitis suppurativa indications.
TypePublic
Founded2007
HQBeverly, US
Websiteipharminc.com

Latest Updates

Employees (est.) (Jun 2019)4(-50%)
Share Price (Oct 2017)$0.8 (-5%)

Key People/Management at Innovation Pharmaceuticals

Leo Ehrlich

Leo Ehrlich

CEO
Arthur Bertolino

Arthur Bertolino

President
Show more

Innovation Pharmaceuticals Office Locations

Innovation Pharmaceuticals has an office in Beverly
Beverly, US (HQ)
100 Cummings Center #151
Show all (1)

Innovation Pharmaceuticals Financials and Metrics

Innovation Pharmaceuticals Revenue

USD

Net income (FY, 2019)

(8.7m)

EBIT (FY, 2019)

(6.5m)

Market capitalization (8-Oct-2018)

38.9m

Cash (30-Jun-2019)

579.0k
Innovation Pharmaceuticals's current market capitalization is $38.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

872.0k1.2m1.9m1.3m1.4m1.2m

R&D expense

6.3m10.5m9.0m12.8m11.4m4.3m

Operating expense total

8.0m13.0m12.7m15.3m13.9m6.5m

EBIT

(8.0m)(13.0m)(12.7m)(15.3m)(13.9m)(6.5m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

General and administrative expense

244.0k275.0k339.0k352.0k249.0k362.0k344.0k331.0k295.0k

R&D expense

1.9m2.3m1.8m2.1m3.0m2.3m2.7m3.2m1.8m

Operating expense total

2.2m2.6m2.2m3.3m3.7m3.0m3.3m3.9m2.4m

EBIT

(2.7m)(2.8m)(2.5m)(3.3m)(3.7m)(3.0m)(3.3m)(3.9m)(2.4m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.0m8.4m6.3m4.1m2.4m579.0k

Current Assets

5.6m8.8m6.7m4.5m2.6m625.0k

PP&E

1.0k

Total Assets

10.9m14.3m11.4m9.1m6.5m4.0m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Cash

7.1m9.5m10.8m7.8m6.2m5.3m5.6m3.9m5.6m1.3m

Current Assets

7.2m9.6m11.4m8.0m6.4m5.8m6.2m4.1m5.7m1.5m

Total Assets

12.5m14.9m17.1m13.5m11.9m11.3m10.9m8.8m10.5m5.8m

Current Liabilities

8.0m7.7m7.3m7.5m7.6m8.4m8.8m8.7m9.3m9.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)(8.7m)

Accounts Payable

815.0k(826.0k)1.7m1.2m(1.5m)(1.1m)

Cash From Operating Activities

(7.5m)(13.1m)(9.9m)(11.7m)(13.3m)(6.3m)

Purchases of PP&E

(43.0k)(9.0k)(68.0k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(2.8m)(2.9m)(2.6m)(5.9m)(9.6m)(3.0m)(3.4m)(3.9m)

Accounts Payable

259.0k1.3m

Cash From Operating Activities

(4.6m)(7.7m)

Purchases of PP&E

(68.0k)
USDY, 2019

Financial Leverage

-1 x
Show all financial metrics

Innovation Pharmaceuticals Online and Social Media Presence

Embed Graph

Innovation Pharmaceuticals News and Updates

Innovation Pharmaceuticals Partnering Provides Momentum For Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need

BEVERLY, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce positive momentum in its efforts to advance programs utilizing Brilacidin for Inflammatory Bowel Disease (IBD).  The Company…

Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases

BEVERLY, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of published Host Defense Protein/Peptide (HDP) basic research insights that reinforce the therapeutic potential of …

Innovation Pharmaceuticals Clinical Trial of Oral Brilacidin in Ulcerative Colitis Program Expected to Commence in December; Top-Line Data in Q1 2020

BEVERLY, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that management is finalizing documentation necessary to initiate the planned Phase 1 clinical trial of oral Bril…

Innovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction Firm

BEVERLY, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company has engaged Locust Walk, a leading global life sciences transaction firm. Locust Walk will seek…

Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon

BEVERLY, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that BDD Pharma, the Company’s formulation partner in the area of Inflammatory Bowel Disease (IBD), has performe…

Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease

BEVERLY, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an award-winning drug delivery company specializing in modified and controlled release oral formulations, …
Show more

Innovation Pharmaceuticals Blogs

Innovation Pharmaceuticals Partnering Provides Momentum for Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need

·       Convened first Joint Development Committee (JDC) meeting ·       Data generated to inform internal Brilacidin development efforts in Ulcerative Colitis·       Goal to develop oral Brilacidin to treat a wide continuum of GI diseases in GI market estimated to hit $48.4 Billion by 2022·       B…

Literature Supporting Therapeutic Potential of Host Defense Peptide/Protein (HDP)-Based Drug Candidates Such as Brilacidin

Innovation Pharmaceuticals wanted to bring attention to recently published Host Defense Peptide/Protein (HDP) research (linked to below) that supports the development of HDP-based therapeutics, including synthetic or mimetic versions, such as Brilacidin.Brilacidin’s Development as an HDP-Mimetic in …

Innovation Pharmaceuticals Engages Locust Walk, a Global Life Sciences Transaction Firm

 ·       Objective to further unlock market potential of pipeline and determine the appropriate path forward to enhance shareholder value·       Locust Walk a global life sciences transaction firm with exceptional strategic insights rooted in their deal experienceBEVERLY, MA – September 30, 2019 (GL…

Innovation Pharmaceuticals Plans for Clinical Trial of Oral Brilacidin for Ulcerative Colitis Program in 4th Quarter 2019

BEVERLY, MA – September 10, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company is planning for the first human trial utilizing an oral formulation of Brilacidin in the program f…

Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Business Development Activities

·       Company building on momentum from recently executed licensing agreement with Alfasigma S.p.A.·       Focus on transitioning to oral formulations of first-in-class drug candidates, and securing additional strategic alliances and licensing dealsBEVERLY, MA – July 29, 2019 (GLOBE NEWSWIRE) Inno…

Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis

·       Over $24M in initial and milestone-based paymentsBEVERLY, MA – July 22, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has executed a license agreement with Alfasigma S.p.A (“Alf…
Show more

Innovation Pharmaceuticals Frequently Asked Questions

  • When was Innovation Pharmaceuticals founded?

    Innovation Pharmaceuticals was founded in 2007.

  • Who are Innovation Pharmaceuticals key executives?

    Innovation Pharmaceuticals's key executives are Leo Ehrlich and Arthur Bertolino.

  • How many employees does Innovation Pharmaceuticals have?

    Innovation Pharmaceuticals has 4 employees.

  • Who are Innovation Pharmaceuticals competitors?

    Competitors of Innovation Pharmaceuticals include Urovant Sciences, Verrica Pharmaceuticals and MultiCell Technologies.

  • Where is Innovation Pharmaceuticals headquarters?

    Innovation Pharmaceuticals headquarters is located at 100 Cummings Center #151, Beverly.

  • Where are Innovation Pharmaceuticals offices?

    Innovation Pharmaceuticals has an office in Beverly.

  • How many offices does Innovation Pharmaceuticals have?

    Innovation Pharmaceuticals has 1 office.